semaglutide recall If Your Bears These Numbers, It's Part of a Nationwide Semaglutide & Tirzepatide Recall: What

Contact your doctor if you experience: Severe abdominal pain or persistent vomiting (possible sign of pancreatitis)

- Handle using appropriate personal protective equipment

Medicare Part D starts January 2027 (after plans opt in)

Through careful monitoring and personalized dosing, we help achieve optimal results while minimizing potential side effects

Results can support informed discussions with your provider about whether medication might complement behavioral work

For patients without the aforementioned comorbidities with the primary goal of glycemic and weight management, GLP-1 and GIP/GLP-1 receptor agonists are recommended.(1) GLP-1 receptor agonists are not only efficacious for glucose lowering and achieving diabetes treatment goals, but have also demonstrated several added benefits in recent studies